Arecor targets oncology and rare orphan diseases in US alliance
Cambridge biopharma business Arecor has extended its multi-product collaboration with a US-based clinical stage biotechnology company.
Under the UK-US collaboration, Arecor will leverage its Arestat™ technology to develop liquid formulations of two proprietary novel products in oncology and a rare genetic orphan condition.
The partner – not identified – is currently funding the development work and has the option to acquire the rights to the formulations and associated Intellectual Property under separate milestone-bearing licenses at pre-agreed financial terms.
The partnership further demonstrates the flexibility of Arecor’s Arestat™ technology platform in delivering formulation solutions in this case for both multi-valent antibodies and recombinant fusion proteins.
Arestat™ is a world leading proprietary formulation technology platform said to significantly enhance the properties of therapeutic proteins and peptides.
The company claims that Arestat™ has the unique potential to deliver superior formulations of both new chemical entities and also existing products which would otherwise not be possible.
Arecor CEO Dr Sarah Howell said: “This multi-collaboration with a fast growing US biotech company demonstrates the adaptability of the Arestat™ platform.
“Not only do these key products represent Arestat™’s ability to support the development of clinical stage assets across a range of therapeutic areas, but also demonstrate the potential of the technology to deliver superior liquid formulations of novel format proteins, further expanding and advancing the application of Arecor’s expertise across the spectrum of product development.”
Arecor is one of a rising number of life science businesses growing globally from a Chesterford Research Park springboard.